Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRSD107 in Chronic Coronary and/or Peripheral Arterial Disease
NCT07318155Phase 2Recruiting
- Sponsor
- Sirius Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of SRSD107 in coronary artery disease (CAD), Peripheral Arterial Disease (PAD), sponsored by Sirius Therapeutics. Started Mar 2025; status: recruiting.
02
Drugs
SRSD107
03
Conditions
coronary artery disease (CAD)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT07318155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318155.